CoChat

Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy

Marais, Gary E., Larson, Kerry K. · 1990 · Annals of Internal Medicine
Cited by 90

The DOI matches its Crossref record.

Abstract

Brief Reports1 February 1990Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil TherapyGary E. Marais, MB, ChB, Kerry K. Larson, MDGary E. Marais, MB, ChB, Kerry K. Larson, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-3-228 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptLovastatin is a new lipid-lowering drug that has shown great promise in the treatment of patients with hypercholesterolemia (1, 2). It is the first available agent in a new class of drugs that inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which catalyzes the rate-limiting step in cholesterol synthesis (3). Lovastatin is well tolerated and few severe adverse effects have been reported (4). Myopathy, defined as muscle pain or weakness associated with markedly elevated creatine kinase levels, has a reported incidence of 0.5% (4). Rhabdomyolysis has been reported in 30% of patients when the drug is used concomitantly with immunosuppressive drugs...References1. HavelHunninghakeIllingworth RDD. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987;107:609-15. LinkGoogle Scholar2. . Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA. 1986;256:2829-34. CrossrefMedlineGoogle Scholar3. Grundy S. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33. CrossrefMedlineGoogle Scholar4. Tobert J. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J. CrossrefMedlineGoogle Scholar5. NormanIllingworthMunsonHosenpud DDJJ. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin [Letter]. N Engl J Med. 1988;318:46-7. CrossrefMedlineGoogle Scholar6. EastAlivizatosGrundyJonesFarmer CPSPJ. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation [Letter]. N Engl J Med. 1988;318:47-8. CrossrefMedlineGoogle Scholar7. Tobert J. Reply. N Engl J Med. 1988;318:48. MedlineGoogle Scholar8. ReavenWitztum PJ. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988;109:597-8. LinkGoogle Scholar9. AyanianFuchsStone JCR. Lovastatin and rhabdomyolysis [Letter]. Ann Intern Med. 1988;109:682-3. LinkGoogle Scholar10. CorpierJonesSuki CPW. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 1988;260:239-41. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From Jerry L. Pettis Memorial Veterans Hospital, Loma Linda, California. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByNutritional and nonnutritional management of the nephrotic syndromeThe Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ ActivationDrug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic ReviewDrug Class Combination–Associated Acute Kidney InjurySafety and efficacy of fibrate–statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysisSafety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysisNutritional and Non-nutritional Management of the Nephrotic SyndromePersistent Use of Against-Label Statin-Fibrate Combinations from 2003-2009 Despite United States Food and Drug Administration Dose RestrictionsEvaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysisRecovery Time in a Case of Gemfibrozil and Simvastatin-Associated RhabdomyolysisToxic MyopathiesEffectiveness of Statin-Gemfibrozil Combination Therapy in Patients With Mixed Hyperlipidemia: Experience of a Community Lipid Clinic and Safety Review From the LiteratureChapter 32 Toxic myopathiesCombination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid DerivativeA safety look at currently available statinsCerivastatin-Induced Rhabdomyolysis: 11 Case ReportsMyopathy and rhabdomyolysis with lipid-lowering drugsAcquired MyopathiesEl tratamiento farmacológico hipolipemiante con estatinas debería ser el más indicado en los individuos con hipercolesterolemia e hipertrigliceridemiaConséquences inattendues dˈun effet indésirable attendu de la cérivastatineRhabdomyolysis and HMG-CoA Reductase InhibitorsStatin—Fibrate Combination TherapyRhabdomyolysis due to combination therapy with cerivastatin and gemfibrozilRhabdomyolysisEffects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot studyInfluenza vaccine—a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of ceriva

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-112-3-228

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 90

Metadata

Authors
Marais, G. E., & Larson, K. K.
Venue
Annals of Internal Medicine
Published
1990-02-01
Volume
112
Issue
3
Pages
228-230
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2063421142
Cited by
90
References
0
FWCI
11.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy. https://app.cochat.ai/papers/10.7326/0003-4819-112-3-228
The paper
Marais, G. E., & Larson, K. K. (1990). Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-112-3-228

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.